SLC5A2 and chronic kidney disease: In adults, other classes of medications such as spherical carbon adsorbents, mineralocorticoid receptor antagonists, and sodium–glucose cotransporter 2 (SGLT2) inhibitors are approved to slow down CKD progression in one or more countries; however, none are indicated for children to date [4–6].